₹ 3,142.36 Cr
2.12%
BSE Healthcare TRI
INF740KA1LE6
100.0
100.0
100
Chirag Dagli
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| DSP Healthcare Fund - Regular Plan - IDCW | 8.22 | 21.5 | 13.33 |
| Benchmark | - | - | - |
Equity
Debt
Others
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved
| Company | Holdings (%) |
|---|---|
| IPCA LABORATORIES LIMITED EQ NEW FV RE .1/- | 9.39 |
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 9.33 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 7.68 |
| Globus Medical Inc | 7.58 |
| Illumina Inc | 6.47 |
| LAURUS LABS LIMITED EQ NEW FV RS. 2/- | 6.29 |
| Sai Life Sciences Limited | 6.02 |
| GLAND PHARMA LIMITED EQ NEW FV Re.1/- | 5.4 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 5.0 |
| ALEMBIC PHARMACEUTICALS LIMITED EQ | 3.28 |
| Sector | Holdings (%) |
|---|---|
| Healthcare | 77.58 |
| Financial Services | 1.43 |
| Consumer Services | 0.56 |